BusinessWeek is running a series of articles that take a look at the various issues surrounding the controversy of implantable microchips. This week, Scott R. Silverman, CEO of VeriChip out of Delray Beach, FL, is defending the technology that led his company to receive the first FDA approval for implantable RFID:
During the FDA approval process we provided 34 studies to the FDA demonstrating the safety of implantable microchips. There have been numerous studies in mice, rats, woodchucks, rabbits, guinea pigs, pigs, and dogs that investigated the microchip and potential adverse effects of inserting it into subcutaneous tissue. None of these studies showed any tumors or other significant problems. It is clear the use of microchips in humans and pets is a safe and a dependable means of identification that has been used in millions of animals for over 15 years and in humans for the past several years. Except for a few vocal naysayers, this product is overwhelmingly embraced by medical professionals and high-risk patients.
There has also been some confusion regarding the VeriMed microchip’s capabilities. The VeriMed microchip is a passive device (it has no power source) that is activated only when read by our scanner. The microchip stores only an identification number and cannot track a person’s whereabouts because it does not have Global Positioning System capability. Some privacy advocates have voiced concerns regarding our microchip but often we find that once people are educated on what the device is: a passive identification tool to identify high-risk patients and their medical records; and what the device isn’t—a GPS tracking device —their concerns are mollified.
More at BusinessWeek…
Related: California Senate Passes Bill Outlawing RFID Skimming